دورية أكاديمية
Phase i trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
| العنوان: | Phase i trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours |
|---|---|
| المؤلفون: | Kozloff, Mark F., Martin, Lainie P., Krzakowski, Maciej J., Samuel, Thomas A., Rado, Thomas A., Arriola, Edurne, Castro-Carpeño, Javier De, Herbst, Roy S., Tarazi, Jamal C., Kim, Sindy T., Rosbrook, Brad P., Tortorici, Michael A., Olszanski, Anthony J., Cohen, Roger B. |
| المساهمون: | UAM. Departamento de Medicina |
| بيانات النشر: | Cancer Research UK |
| سنة النشر: | 2014 |
| المجموعة: | Universidad Autónoma de Madrid (UAM): Biblos-e Archivo |
| مصطلحات موضوعية: | Axitinib, Chemotherapy, Non-small cell lung cancer, Pharmacokinetics, Solid tumours, Medicina |
| الوصف: | BACKGROUND: This phase I dose-finding trial evaluated safety, efficacy and pharmacokinetics of axitinib, a potent and selective secondgeneration inhibitor of vascular endothelial growth factor receptors, combined with platinum doublets in patients with advanced non-small cell lung cancer (NSCLC) and other solid tumours. METHODS: In all, 49 patients received axitinib 5mg twice daily (b.i.d.) with paclitaxel/carboplatin or gemcitabine/cisplatin in 3-week cycles. Following determination of the maximum tolerated dose, a squamous cell NSCLC expansion cohort was enroled and received axitinib 5mg b.i.d. with paclitaxel/carboplatin. RESULTS: Two patients experienced dose-limiting toxicities: febrile neutropenia (n¼1) in the paclitaxel/carboplatin cohort and fatigue (n¼1) in the gemcitabine/cisplatin cohort. Common nonhaematologic treatment-related adverse events were hypertension (36.7%), diarrhoea (34.7%) and fatigue (28.6%). No gradeX3 haemoptysis occurred among 12 patients with squamous cell NSCLC. The objective response rate was 37.0% for patients receiving axitinib/paclitaxel/carboplatin (n¼27) and 23.8% for patients receiving axitinib/gemcitabine/cisplatin (n¼21). Pharmacokinetics of axitinib and chemotherapeutic agents were similar when administered alone or in combination. CONCLUSION: Axitinib 5mg b.i.d. may be combined with standard paclitaxel/carboplatin or gemcitabine/cisplatin regimens without evidence of overt drug–drug interactions. Both combinations demonstrated clinical efficacy and were well tolerated. ; This study was sponsored by Pfizer Inc. Support was provided in part by National Institutes of Health grant P30 CA006927 to the Fox Chase Cancer Center. We thank the patients who participated in this study and the physicians who referred them, as well as the study coordinators and data managers, Shelley Mayfield and Carol Martins at Pfizer Inc. for support of the study conduct, and Gamal ElSawah, Pfizer Medical Affairs, for his review of the manuscript. Medical writing support was provided by Joanna ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | British Journal of Cancer; http://dx.doi.org/10.1038/bjc.2012.406Test; British Journal of Cancer 107.8 (2012): 1277-285; 0007-0920 (print); 1532-1827 (online); http://hdl.handle.net/10486/662415Test; 1277; 1285; 107 |
| DOI: | 10.1038/bjc.2012.406 |
| الإتاحة: | https://doi.org/10.1038/bjc.2012.406Test http://hdl.handle.net/10486/662415Test |
| حقوق: | © 2012 Cancer Research UK All rights reserved 0007-0920/12 ; openAccess |
| رقم الانضمام: | edsbas.9C116CD5 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/bjc.2012.406 |
|---|